Borui Biotech Hong Kong IPO Prospectus Expires After 6 Months, Submitted in January

According to Zhitong Finance, Borui Biotech's Hong Kong IPO prospectus filed on January 6, 2026, expired on July 6, 2026, after the standard six-month validity period. Huatai International and J.P. Morgan served as joint sponsors for the listing. Borui Biotech is a China-based integrated biopharmaceutical company focused on immunotherapy solutions for autoimmune, inflammatory, tumor immunology, and hematologic malignancy patients.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments